# CONMED Corp > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/CONMED Corp). ## Overview CONMED Corp is a U.S.-based medical technology company focused on devices and equipment used in surgical procedures. Its portfolio spans orthopedic surgery and general surgery, with products used in sports medicine, lower-extremity procedures, minimally invasive laparoscopic and gastrointestinal surgery, electrosurgery, smoke evacuation, and cardiac monitoring. The company sells primarily to hospitals, surgery centers, surgeons, distributors, and large healthcare purchasing organizations, and it supports these customers through direct sales and distributor channels. CONMED manufactures substantially all of its products in the United States and Mexico and markets them globally, with a meaningful share of revenue coming from international markets. The business is characterized by a high mix of single-use products, which creates recurring demand tied to procedure volumes and installed capital equipment placements. ## Products & services • Orthopedic surgery instruments, implants and imaging systems • Sports medicine and lower-extremity instrumentation • Endo-mechanical laparoscopic and GI surgical devices • Electrosurgical generators and related instruments • Smoke evacuation and clinical insufflation products • Cardiac monitoring products and electrodes • Gastroenterology and pulmonology energy platform - **Orthopedic surgery** (42%) — Sports medicine, lower-extremity, small bone, large bone and powered surgical products used in orthopedic procedures. - **General surgery** (58%) — Minimally invasive laparoscopic and gastrointestinal devices, electrosurgery, smoke evacuation, insufflation and monitoring products. - Orthopedic surgery instruments, implants and imaging systems - Sports medicine and lower-extremity instrumentation - Endo-mechanical laparoscopic and GI surgical devices - Electrosurgical generators and related instruments - Smoke evacuation and clinical insufflation products - Cardiac monitoring products and electrodes - Gastroenterology and pulmonology energy platform ## Customers CONMED sells to a broad base of healthcare providers that use its devices in operating rooms and procedural suites. Its core customers include surgeons, hospitals, surgery centers, group purchasing organizations, integrated delivery networks, and medical specialty distributors. The company also serves large national and regional accounts, including Veterans Administration and other federal hospitals in the U.S. Customer demand is driven by procedure volumes, product performance, regulatory approval, and the ability to reduce supplier complexity and total cost of care. No single customer accounted for more than 10% of net sales in 2025, 2024, or 2023, which indicates a diversified customer base. - **Hospitals and health systems** (primary) — Buy orthopedic and general surgery devices for operating rooms, procedural suites and inpatient care, prioritizing reliability, breadth of portfolio and supply continuity. - **Surgery centers** (primary) — Purchase recurring single-use surgical products and capital equipment for outpatient procedures, where efficiency and procedure-specific performance matter. - **GPOs and IDNs** (primary) — Influence purchasing decisions for large healthcare networks that want fewer suppliers, standardized products and better pricing. - **Medical specialty distributors** (secondary) — Buy products for resale to healthcare providers, especially where customers prefer third-party inventory management and local distribution support. - **Government and federal healthcare accounts** (secondary) — Includes Veterans Administration and other federal hospitals that buy through institutional procurement channels. - Hospitals buying surgical devices for routine and specialty procedures - Surgery centers seeking recurring single-use products and accessories - Surgeons and clinicians specifying tools based on procedure needs - GPOs and IDNs consolidating suppliers to lower cost and complexity - Medical specialty distributors reselling to healthcare providers - Veterans Administration and federal hospitals purchasing through contracts ## Geography CONMED is headquartered in Largo, Florida and manufactures substantially all of its products in the United States and Mexico. The company markets products domestically and internationally, with international sales approximating 44% of consolidated net sales in 2025 and 43% in the first nine months of 2025. Management identifies Europe, Latin America, Canada and the Asia/Pacific Rim as principal international markets, which makes the business meaningfully exposed to foreign exchange, tariffs, import/export rules and local healthcare purchasing conditions. The company also sells through third-party distributors in some regions, including limited exposure to Ukraine and the Middle East, but those sales were described as not material. This geographic mix matters because manufacturing, distribution and tariff exposure are split across North America and multiple overseas end markets. - **United States** (56%) — Estimated from the reported international sales share of approximately 44%. - **International** (44%) — Estimated from management disclosure that international sales approximated 44% in 2025. - Headquartered in Largo, Florida, which anchors corporate and commercial operations - Manufacturing concentrated in the United States and Mexico - International sales are a large part of the business, around 44% of revenue - Principal overseas markets include Europe, Latin America, Canada and Asia/Pacific - Some sales go through third-party distributors, increasing channel dependence abroad - Exposure to tariffs and border taxes affects both U.S. imports and exports ## Strategy CONMED's strategy centers on portfolio optimization, manufacturing efficiency and geographic diversification. Management has said it continuously reviews the product portfolio, pursuing acquisitions and distribution arrangements where they add scale, technology or market access, while discontinuing products that no longer fit the strategy. The company is also focused on reducing operating costs and improving supply chain and manufacturing processes, reflecting pressure from inflation, tariffs and supply chain disruption. International expansion remains important because management sees growth opportunities outside the United States, especially in Europe, Latin America, Canada and Asia/Pacific. The planned exit from the Gore VIABIL biliary endoprosthesis distribution agreement and the remaining gastroenterology product line indicates a sharper focus on core surgical categories with better strategic fit and margin potential. - **Portfolio optimization and product-line pruning** (short-term) — Management wants to focus resources on products that fit the core surgical strategy and improve margins. - **Manufacturing and supply chain efficiency** (short-term) — Inflation, tariffs and supply chain challenges are pressuring costs, so operational improvements are needed to protect profitability. - **International growth and diversification** (medium-term) — Management sees meaningful growth opportunities outside the U.S. and wants to reduce dependence on any single market. - Prune non-core products and concentrate capital on core surgical franchises - Use acquisitions and distribution deals to add technology and market access - Improve manufacturing efficiency and reduce inventory and operating costs - Expand internationally to diversify growth beyond the U.S. market - Maintain physician and medical community relationships to support adoption - Exit lower-priority gastroenterology distribution activities - Preserve liquidity for R&D, acquisitions, debt service and shareholder returns ## Risks CONMED faces demand risk tied to healthcare spending, procedure volumes and broader economic conditions, since its products are used in elective and scheduled surgeries. The company is exposed to competitive and innovation risk because larger rivals may develop new technologies faster, and its products could become obsolete if it fails to keep pace. Regulatory, reimbursement and approval risk is important in medical devices because delays in approvals or lack of clinical evidence can slow adoption of new products. Operationally, inflation, tariffs, supply chain disruption and border taxes can raise costs and compress margins, while international sales expose the company to political, trade and foreign-government restrictions. The planned exit from the Gore VIABIL distribution agreement also creates transition risk as the company replaces revenue from a product line that generated meaningful sales in 2025. - **Dependence on healthcare procedure volumes** [high] — Revenue is tied to surgical procedures, many of which can be delayed during economic weakness, staffing shortages or public health disruptions. - **Product innovation and competitive pressure** [high] — The company competes against larger medical device firms with greater R&D and commercialization resources, which can reduce demand for CONMED products. - **Tariffs and trade restrictions** [high] — Manufacturing and sales span the U.S., Mexico and international markets, so tariffs and border taxes can directly affect cost structure and pricing. - **Regulatory and approval delays** [medium] — Medical devices require approvals and clinical evidence, and delays can postpone launches or limit adoption of new products. - **Transition away from Gore VIABIL and gastroenterology** [high] — The company is ending a distribution agreement that contributed meaningful sales, so replacement revenue and margin mix must be managed carefully. - Procedure volumes can fall when hospitals delay elective surgeries or face staffing shortages - Competition from larger medical device companies can pressure pricing and innovation - Regulatory approval delays can slow new product launches and market acceptance - Tariffs, import/export rules and border taxes can raise manufacturing and distribution costs - Supply chain disruptions and inflation can increase operating costs and reduce margins - International political and trade risks can affect distributor sales and market access - Exit of the Gore VIABIL distribution business creates near-term revenue transition risk ## Accounting CONMED's reported results are influenced by judgment-heavy areas such as goodwill and intangible assets, contingent consideration and pension obligations. Because the company grows partly through acquisitions, goodwill and acquired intangibles can become material and may require impairment testing if performance weakens or market assumptions change. Revenue and margin can also be affected by the mix of single-use products versus capital equipment and related accessories, since the installed base can drive recurring consumable sales over time. Quarterly results may fluctuate with procedure timing, customer ordering patterns, tariff-related cost changes and the timing of product exits or distribution transitions. Investors should also watch debt-related accounting and liquidity disclosures because the company uses borrowing capacity, acquisitions and shareholder returns as part of capital allocation. - **Goodwill and intangible assets** — Could create non-cash charges and affect equity and earnings - **Contingent consideration** — Can introduce periodic remeasurement gains or losses - **Pension benefit obligation** — Can move operating expense and balance sheet obligations - **Product mix and revenue timing** — Affects quarterly comparability and gross margin - Goodwill and intangible asset impairment can materially affect reported earnings - Contingent consideration from acquisitions can create valuation and remeasurement volatility - Pension benefit obligation estimates can move with discount rates and actuarial assumptions - Single-use product mix affects gross margin and recurring revenue visibility - Capital equipment sales can create follow-on consumable demand over time - Quarterly results can vary with procedure timing, tariffs and product-line exits --- *Last updated: 2026-08-11T04:46:26.928578+00:00*